Grifols completes patient follow-up in phase 3 alpha-1 lung study

August 10, 2026 7:01 AM

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found